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For more than 20 years, anthelmintics of the macrocyclic lactone (ML) drug class have been widely and
effectively used as preventives against the canine heartworm, Diroﬁlaria immitis. However, in recent years
an increased number of lack of efﬁcacy (LOE) cases are being reported, in which dogs develop mature
heartworm infections despite receiving monthly prophylactic doses of ML drugs. While this situation
is raising concerns that heartworms may be developing resistance to MLs, compelling evidence for this
is still lacking. Resolution of this dilemma requires validated biological or molecular diagnostic assays,
but, unfortunately, no such tests currently exist. To address this need, we developed and optimized a lar-
val migration inhibition assay (LMIA) for use with D. immitis third-stage larvae. The LMIA was used to
measure the in vitro dose–response of two ML drugs (ivermectin and eprinomectin) on a known ML-
susceptible laboratory strain of D. immitis. A nonlinear regression model was ﬁt to the dose–response
data, from which IC50 values were calculated; the mean IC50 and 95% conﬁdence interval for IVM was
4.56 lM (1.26–16.4 lM), greater than that for EPR at 2.02 lM (1.68–2.42 lM), and this difference was
signiﬁcant (p = 0.0428). The R2 value for EPR assays (0.90) was also greater than that for IVM treatment
(0.71). The consistency and reproducibility of the dose–response data obtained with this assay suggests
that it may be a useful technique for investigating the relative susceptibilities to ML drugs in other D.
immitis populations.
 2013 The Authors. Published by Elsevier Ltd. Open access under CC BY-NC-ND license.1. Introduction Treatment of mature heartworm infection is costly and canThe canine heartworm (Diroﬁlaria immitis) is an important ﬁlar-
ial nematode parasite of dogs, cats, and other animals. The deﬁni-
tive host becomes infected through the bite of mosquitoes
harboring infective third-stage larvae (L3), which penetrate the bite
wound and invade the subcutaneous tissues. Over a period of
approximately 2 months, the larval stages of D. immitis migrate
through the subcutaneous tissues and musculature before pene-
trating into the vasculature. Once in the vasculature, immature
adult worms migrate to the pulmonary arteries and the right side
of the heart, where they mature to adults (Kotani and Powers,
1982). Tissue-migrating larval stages are not associated with any
recognizable pathology; however, once in the vasculature, worms
can cause signiﬁcant damage and life-threatening disease (Bow-
man and Atkins, 2009).cause serious adverse side effects, thus prevention by monthly
administration of drugs that interrupt larval development is
widely used (Bowman and Atkins, 2009). All compounds currently
used for prevention of adult heartworm infection are members of
the macrocyclic lactone (ML) drug class. In 1987, ivermectin be-
came the ﬁrst ML drug approved for use as a heartworm preventive
(Campbell, 1989), and since then, products containing other ML
drugs (milbemycin oxime, selamectin, and moxidectin) have been
introduced. The US Food and Drug Administration (FDA) requires
that all heartworm preventives achieve 100% efﬁcacy when admin-
istered according to label directions (Hampshire, 2005). Therefore,
when owner compliance with label directions is exact, no adult
worms should develop in a dog administered one of these prod-
ucts. However, in recent years the FDA has received increasing re-
ports of cases where mature worms develop in dogs despite
evidence that monthly preventives were administered in a compli-
ant fashion (Hampshire, 2005). These lack of efﬁcacy (LOE) cases,
are raising doubts that ML drugs achieve 100% protection (Geary
et al., 2011). The two most obvious and common explanations
for these LOE cases are (1) a lack of full compliance by the pet own-
ers, which cannot be properly tested, or (2) that D. immitis has
developed resistance to the ML drugs.
Resistance to the ML drugs is highly prevalent throughout the
world in numerous species of gastrointestinal nematodes of
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in vitro bioassays have been developed and validated to detect
ML resistance in many of these species (Taylor et al., 2002). One
of these, the larval migration inhibition assay (LMIA) has already
been successfully applied to several important species of nematode
pathogens of sheep and cattle for diagnosis of ML resistance Kotze
et al., 2006; Demeler et al., 2010) and appears particularly amena-
ble for use with D. immitis.
Evidence suggests that ML drugs exert their anthelmintic effects
on nematodes by binding to glutamate-gated chloride channels
(GluCls) and hyperpolarizing motor neurons, resulting in paralysis
and death (Wolstenholme and Rogers, 2005). This paralytic action
of the ML drugs is the rationale behind the development of the
LMIA, which measures the ability of larvae to migrate across a ﬁne
mesh sieve following incubation with increasing concentrations of
drug. Motility of the infective L3 of heartworms is critical for both
the initial infection process, as well as for migration through the
subcutaneous and muscular tissues of the canine host in order to
gain access to the vasculature. Furthermore, the L3 is one of the tar-
gets (along with the fourth-stage larvae) of monthly preventive
treatment with ML drugs. Since L3 can be produced in large num-
bers in properly equipped laboratories, this appears to be the ideal
life cycle stage of D. immitis for use in an in vitro bioassay, and the
LMIA appears to be the most suitable bioassay for quantifying the
susceptibility of L3 to the paralytic effects of ML drugs.
In this study, we optimized the LMIA for use with D. immitis L3.
We then measured the ML susceptibility of a laboratory heart-
worm strain in the LMIA using both ivermectin and eprinomectin.
This generated reproducible dose–response data, to which we ap-
plied a variable-slope nonlinear regression model, enabling us to
calculate IC50 values as a means of characterizing the in vitro sus-
ceptibility to these drugs. Validation of the LMIA for identifying re-
duced susceptibility in heartworm populations would provide an
extremely valuable tool for monitoring the emergence and spread
of anthelmintic resistance in D. immitis.2. Materials and methods
2.1. Parasites
An ML-susceptible strain of D. immitis (2005 Missouri strain)
maintained and passaged in beagle dogs at the University of Geor-
gia (Athens, GA) was used in this study. This strain was originally
collected in 2000 from a dog at a Missouri animal pound, and while
this donor dog was not treated with anyMLs thereafter, prior treat-
ment records are not available. Third-stage larvae were obtained
by feeding microﬁlaremic blood to Aedes aegypti mosquitoes
(black-eyed Liverpool strain) using artiﬁcial blood feeders, as pre-
viously described (McCall, 1981). Fourteen days after feeding, L3
were obtained by gently crushing the infected mosquitoes, rinsing
them onto a 32 lm mesh sieve set in either a Petri dish or a Baer-
mann apparatus, and soaking them in warm Hanks’ balanced salt
solution. The Brugia pahangi L3 (FR3 strain) used in some of the
optimization experiments were obtained in the same manner,
and are also maintained in beagle dogs at the University of Georgia.2.2. Drug solutions
ML stock solutions (10 mM) were prepared by dissolving pow-
dered ivermectin or eprinomectin (Sigma, St. Louis, MO) in DMSO
(>99.5%; Sigma). Stock solutions were diluted with additional
DMSO into 100 working solutions ranging from 0.0312 to
2.0 mM. These were then added to culture media at a rate of 1%
(v/v) to yield the concentrations used in the LMIA (0.312–20 lMin 1% DMSO). For each drug, the maximum concentration tested
was restricted by its solubility in 1% DMSO.2.3. Larval migration assay optimization
2.3.1. Media
RPMI-1640 (Lonza BioWhittaker, Basel, Switzerland) media
were prepared with 100 U/ml penicillin (Gibco-Invitrogen, Carls-
bad, CA), 100 mg/ml streptomycin (Gibco-Invitrogen), 40 lg/ml
gentamicin (Sigma). For use in the assays, ivermectin or eprino-
mectin in the concentrations detailed above were added to the
RPMI, or only DMSO (1%) in the no-drug controls. NCTC/IMDM
(NI) media were prepared from equal parts NCTC medium (Sigma)
and IMDM (Sigma) with L-glutamine (200 mM; Sigma) added to a
concentration of 2 mM and with 100 U/ml penicillin (Gibco-
Invitrogen, Carlsbad, CA), 100 mg/ml streptomycin (Gibco-
Invitrogen).2.3.2. DMSO concentration
The LMIA was performed with the Missouri strain of D. immitis
using a 48 h incubation period and 2 h migration period. Fifty lar-
vae per well were cultured in a 24-well plate in RPMI-1640 with
antibiotics, as described above, with DMSO concentrations of 0%,
1%, and 2%. Assay results were scored as described for the opti-
mized LMIA. Each concentration was tested in triplicate in three
separate experiments.2.3.3. Migration period
Migration tubes were prepared using a method modiﬁed from
Wagland et al. (1992) and set in 400 ll RPMI-1640 plus antibiotics
in the wells of a 48-well culture plate. A square of 20 lmmesh was
secured over the bottom of each glass migration tube and held in
place by a polymer collar ﬁt around the tube. Tubes were sus-
pended 2 mm above the bottom of the plate by a rubber o-ring
ﬁt around each collar. In a 100 ll volume, 50 B. pahangi L3 were
introduced to each of three migration wells. Larvae were allowed
to migrate while incubating at 37 C and 5% CO2. For the ﬁrst
3:45 h, the migration tubes were transferred to new wells in the
plate every 15 min, and the tubes were ﬁnally removed 24 h after
the beginning of the experiment. The number of L3 to migrate over
each time interval was then determined by counting the larvae in
each well.2.3.4. Incubation period
The LMIA was performed with the Missouri strain of D. immitis
using either a 48 or 72 h incubation period and 2 h migration per-
iod. Fifty larvae per well were cultured in a 24-well plate in RPMI-
1640 medium with 1% DMSO. Four independent experiments were
performed, with each group tested in triplicate.2.3.5. Mesh size
The LMIA was performed with the Missouri strain of D. immitis
using a 48 h incubation period and 2 h migration period. Fifty lar-
vae per well were cultured in a 24-well plate in RPMI-1640 med-
ium with eprinomectin (0.625–50 lM) in 1% DMSO or in a
DMSO-only control. Larvae were allowed to migrate through nylon
mesh of either 25 or 30 lm pore size. Three independent experi-
ments were performed, with each group tested in triplicate.
To determine the effect of larval diameter on migration, 25 D.
immitis L3 per well were cultured in a 24-well plate as above. Lar-
vae that successfully migrated in the LMIA (n = 12) and those that
failed to migrate (n = 12) were measured using an eyepiece
micrometer on an inverted compound microscope (IX51; Olympus,
Center Valley, PA) at 400 magniﬁcation.
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After collection from mosquitoes, D. immitis L3 were washed in
RPMI-1640 and added to individual wells of a 24-well tissue cul-
ture plate (30 larvae per well) in 1 ml RPMI-1640 containing anti-
biotics and drug. Assay plates were then incubated at 37 C and 5%
CO2 for 48 h. Following this incubation period, acrylic migration
tubes were placed into a new 24-well migration plate (Fig. 1);
migration tubes were set in rows of six on a horizontal acrylic
bar, as described by Demeler et al. (2010), and bottomed with
25 lm nylon mesh screens (Sefar, Inc., Heiden, Switzerland). With
the migration tubes in place, 1.4 ml of culture medium warmed to
37 C was added over the tube in each well; drug concentrations in
the media added to each well corresponded to those in the incuba-
tion plate. Using a dissecting microscope, all 30 larvae in each well
of the incubation plate were collected and gently transferred in a
volume of 200 ll to the corresponding migration tube. Once all
the L3 were transferred to migration tubes, they were placed back
into the incubator at 37 C and 5% CO2 for a 2 h migration period
during which motile larvae may pass through the mesh screen
(Supplementary video 1). After 2 h, the migration tubes were
gently removed and the larvae that had migrated into each well
of the migration plate were enumerated during examination with
an inverted compound microscope. Three experiments were per-
formed for each drug (ivermectin and eprinomectin) with concen-
trations tested in triplicate for each experiment.
2.5. Statistics
Differences in migration following incubation for 48 and 72 h
(without drug) and differences in migration through meshes of dif-
ferent size were calculated using a one-tailed unpaired t-test. Cor-
relation between larval diameter and the ability to migrate was
calculated as a point-biserial correlation coefﬁcient, with signiﬁ-
cance assessed by application of a two-tailed t-test.
Percent inhibition of migration was calculated for each well
based on the number of larvae failing to migrate corrected for
the percent of larvae that did not migrate in the no-drug control
wells. Sigmoidal dose–response curves were calculated in Graph-
Pad Prism version 5 (GraphPad Software, Inc., San Diego, CA)Fig. 1. Larval migration inhibition assay procedure. (A) Larvae are incubated in media
transferred into migration tubes, which are suspended over the migration plate. The larva
migration plate. (C) Migration tubes are gently removed from the migration plate and tusing a variable slope nonlinear regression model. A four-parame-
ter logistic equation was applied using global curve-ﬁtting, with
the bottom of the curves constrained to zero. For each treatment,
the IC50 and IC95 (deﬁned as the concentration effecting inhibition
halfway between zero and the maximal response, and 95% of the
maximal response, respectively) were calculated. R2 values and
95% conﬁdence intervals were calculated by GraphPad Prism. Dif-
ferences between the IC50 values of IVM and EPR-treated groups
were calculated using the extra sum-of-squares F test.
3. Results
3.1. Migration period
B. pahangi, a ﬁlarioid parasite closely related to D. immitis was
used in some preliminary experiments with the LMIA, since this
parasite is easier to cycle and was readily available through the
FR3. In these early experiments, we observed that almost all larvae
that successfully migrated over 24 h did so within the ﬁrst 2 h of
incubation (mean ± SD = 99.2 ± 6.56%; Fig. 2). To ensure a conve-
nient yet sufﬁciently long migration period, the migration rate of
D. immitis L3 over 1 h was determined, followed immediately by
an additional 1 h in a separate migration plate. Signiﬁcantly more
larvae migrated over the combined 2 h (83%) period than 1 h
(77%; p = 0.037), therefore a 2 h migration period was used for this
LMIA.
3.2. Media and DMSO content
To determine the optimal culture medium for use in the D. imm-
itis LMIA, RPMI- and NI-based media with added antibiotics were
compared. Six groups of 50 L3 were incubated in each medium
with no difference observed in migration rates (p = 0.81; data not
shown). The RPMI-based medium was chosen for future assays be-
cause of its ease of preparation and convenience.
To solubilize macrocyclic lactone anthelmintics in an aqueous
media it is necessary to use DMSO, but this solvent is known to
negatively affect nematode viability. To determine an appropriate
solvent concentration, larvae were incubated in media containing
1%, 2%, or no DMSO and their migration rates assessed. While nowith or without drug for 48 h in the 24-well incubation plate. (B) Larvae are then
e are then allowed to migrate for 2 h through a 25 lmmesh and are collected in the
he numbers of larvae that successfully migrated are enumerated.
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Fig. 2. Rate of ﬁlarial larval migration. Fifty untreated Brugia pahangi L3 were
allowed to migrate across a 20 lmmesh in each migration tube (n = 3). Tubes were
transferred to new wells every 15 min for the ﬁrst 3:45 h and ﬁnally removed 24 h
after the beginning of the experiment.
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DMSO group (p = 0.39), a signiﬁcant decrease was noted when lar-
vae were exposed to 2% DMSO (p = 0.018; data not shown). Based
on these data, 1% DMSO was used in the LMIA culture medium for
all further experiments.3.3. Incubation period
To allow sufﬁcient exposure of the larvae to the drug without
inducing an excessive reduction in migration of the untreated con-
trol larvae, it was necessary to optimize the incubation period.
Comparison of the LMIA performed using 48 h or 72 h incubation
periods showed that migration rates were signiﬁcantly lower fol-
lowing the longer incubation (p = 0.011; Fig. 3). Furthermore, the
logIC50 for each assay was not signiﬁcantly different (p = 0.51);
therefore, a 48 h incubation period was selected for use in all fu-
ture assays.3.4. Larval diameter and mesh size
The pore size of the mesh sieve is a discriminating parameter
for parasite migration in the LMIA. We observed that the diameter
of L3 varied somewhat, so we wanted to conﬁrm that this variable
would not affect migration rates in the LMIA. Larvae that had either
migrated or failed to migrate through a 25 lm mesh were mea-
sured using an ocular micrometer in an inverted compound micro-
scope (Fig. 4). The largest D. immitis L3 diameter measured was
25 lm (mean ± SEM = 20.6 ± 0.268 lm). No correlation between
migration and larval diameter was observed (p = 0.95), providingFig. 3. Effect of drug incubation period on larval migration. The LMIA was
performed using 48 and 72 h incubation periods with eprinomectin. To more
accurately compare the effect of incubation time on migration, data are not
corrected for control inhibition. Dotted lines indicate logIC50 values. Each data point
represents mean ± SD, nP 12 from four independent assays.evidence that migration rates were not a function of variation in
larval diameter.
Mesh size was selected so that it was no smaller than the largest
larval diameter, yet remained ﬁne enough to restrict the passage of
immotile larvae. Given the commercial availability of mesh with a
variety of pore sizes, migration rates through 25 and 30 lm mesh
sieves were compared. No reduction in migration was observed for
the smaller mesh size compared to the larger (three independent
experiments, p = 0.38) for worms incubated without drug. How-
ever, migration of drug-treated larvae at the highest concentration
tested was signiﬁcantly reduced with the 25 lm mesh (p = 0.034;
data not shown). A small percentage of larvae were observed to mi-
grate through the 25 lm mesh at the highest drug concentrations
tested, but it was conﬁrmed visually that this was due to larval
motility, and not the incidental passage of immotile larvae. In con-
trast, with the 30 lm mesh, small numbers of immotile larvae
were found to pass through the mesh. Given these data, the
25 lm mesh size was selected as being optimal for use in this
assay.
3.5. Optimized larval migration inhibition assay
The mean migration inhibition rates in the control wells were
consistently less than 10% (mean ± SD = 7.78 ± 7.75%) in most as-
says, indicating that D. immitis L3 retain high levels of motility after
48 h of incubation in RPMI media containing 1% DMSO. However,
mean inhibition at the highest drug concentrations tested infre-
quently exceeded 90% (mean ± SD = 80.7 ± 13.9%). Dose–response
curves were plotted for the ML-susceptible Missouri heartworm
strain treated with either ivermectin or eprinomectin (Fig. 5) at
concentrations ranging from 0.312 to 20 lM. The IC50 values for
D. immitis L3 exposed to ivermectin and eprinomectin were 4.56
and 2.02 lM, respectively, and these values were signiﬁcantly dif-
ferent from each other (p = 0.0428). The calculated IC95 values were
less reliable, characterized by very large 95% conﬁdence intervals,
especially for ivermectin (Table 1). The ﬁt of each curve to the glo-
bal nonlinear regression model was expressed as an R2 value, and
higher values were consistently found with eprinomectin, suggest-
ing that eprinomectin is a better choice for use in this in vitro
bioassay.
4. Discussion
The emergence of D. immitis that are resistant to macrocyclic
lactone anthelmintics would represent a serious threat to canine
health. However, there still is no consensus on the issue of whether
ML resistance has emerged or if LOE cases are sufﬁcientlyFig. 4. Effect of larval diameter on migration through 25 and 30 lm mesh sieves.
The diameters of larvae that successfully migrated in the LMIA and those that failed
to migrate were measured. Horizontal line indicates mean, n = 12.
Fig. 5. Larval migration inhibition assay dose–response curves. Data from the ML-
susceptible Missouri (2005) D. immitis strain are plotted for both ivermectin
(squares) and eprinomectin (circles). Dotted lines indicate mean logIC50 values,
with solid horizontal bars representing the 95% conﬁdence interval of each. Each
data point represents the mean ± SD for three independent assays.
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issue is the absence of a validated diagnostic test for measuring
resistance in D. immitis. Here we report the development and opti-
mization of an in vitro bioassay for measuring the in vitro suscep-
tibility of D. immitis L3 to ML anthelmintics. Using an established
ML-susceptible laboratory isolate, we demonstrated the ability to
reproducibly measure the in vitro dose–response characteristics
of D. immitis L3 to ivermectin and eprinomectin.
Considering the biology and epidemiology of D. immitis and its
extreme sensitivity to ML drugs, the emergence of resistance in
this parasite has historically been considered unlikely (Prichard,
2005). However, increasingly common LOE reports have raised
concerns that ML resistance is developing in heartworms (Hamp-
shire, 2005). In addition, several recent studies have reported ge-
netic structural differences and/or sequence changes in some
heartworm isolates leading these authors to conclude that resis-
tance is present (Bourguinat et al., 2011a,b). Single nucleotide
polymorphisms (SNPs) have been reported to occur in a gene
encoding a P-glycoprotein, a class of proteins implicated in re-
duced ML efﬁcacy against the ﬁlarioid Onchocerca volvulus (Prich-
ard and Roulet, 2007), and associated with ML-resistance in
Haemonchus contortus (Xu et al., 1998). Examining multiple D.
immitis isolates, Bourguinat et al. (2011b) reported a correlation
between the frequency of a pair of SNPs and reduced in vitro ML
efﬁcacy on microﬁlariae in an isolate-speciﬁc manner. In one case,
a dog originating from Louisiana demonstrated persistent microﬁl-
aremia following multiple high-dose ML treatments (Bourguinat
et al., 2011a). A high frequency of the aforementioned genotype
was observed in this population of microﬁlariae, prompting the
authors to cite ML resistance as the cause of this anomaly. How-
ever, even after numerous high-level doses of ML drugs, only 45%
of the recovered microﬁlariae carried the SNPs suspected to be
associated with resistance. Therefore, the signiﬁcance of these
SNPs as markers for resistance remains unclear. Though seriousTable 1
Larval migration inhibition assay results. IC50 and IC95 values of the ML-susceptible
Missouri (2005) D. immitis strain are shown with their 95% conﬁdence intervals (CI)
for both ivermectin and eprinomectin. The R2 values are presented as a measure of
how well dose–response data ﬁt the nonlinear regression model used in this study.
Three independent assays were performed for each group.
Treatment
Ivermectin Eprinomectin
IC50 (lM) 4.56 2.02
95% CI 1.26–16.4 1.68–2.42
IC95 (lM) 142 9.20
95% CI 7.02–2890 5.28–16.0
R2 0.71 0.90concerns of ML-resistance in D. immitis have existed for several
years, no deﬁnitive studies that demonstrate this resistance under
controlled conditions have yet been reported, and no assays for the
detection of resistance have been validated.
The LMIA developed in this study was modiﬁed from those ap-
plied to gastrointestinal nematodes of ruminants for assessing
drug-resistance status. Several other in vitro bioassays also exist
for diagnosing ML resistance in gastrointestinal nematodes, the
most commonly used being the larval development assay (LDA).
However, the dissimilar biology of the ﬁlarioids prevents the appli-
cation of this assay, and thus the LMIA was selected as the most
viable and applicable technique. Extensive modiﬁcation of the as-
say was required for optimal performance with ﬁlarial nematodes,
which are, by comparison, highly sensitive to environmental expo-
sure. In particular, four aspects of the D. immitis LMIA were the fo-
cus of optimization: (1) incubation time was adjusted to allow
sufﬁcient ML exposure while maintaining control parasite viabil-
ity; (2) the medium and antibiotics were optimized for ﬁlarioid
culture conditions; (3) the mesh size (25 lm) was selected for opti-
mal discrimination of motile vs. non-motile D. immitis L3; and (4)
individual L3 were counted and placed in wells of the assay plate
rather than estimated numbers being aliquoted in known volumes
of liquid, as is typically done in protocols for ruminant nematodes.
This was done to reduce well-to-well variability given the rela-
tively small numbers of D. immitis L3 that could be readily obtained
for each experiment.
The optimized assay reported here permitted a consistent high-
level migration in untreated control parasites and yielded consis-
tent, reproducible dose–response data. This permitted us to calcu-
late accurate IC50 values for each drug examined. However, even at
the highest ML concentrations that could be solubilized, complete
inhibition of larval migration was rarely observed; the mean inhi-
bition at 20 lMwas 88.8% (SD = 6.89%) for eprinomectin and 70.0%
(SD = 14.0%) for ivermectin. Therefore, it was not possible to accu-
rately measure IC95 values, leading to very wide 95% conﬁdence
intervals. Higher ML concentrations were not used owing to their
poor solubility at the solvent level used (1% DMSO). Increasing
the solvent level permits the use of higher ML concentrations,
but this adversely affects parasite viability. Since it is critical that
the untreated control parasites maintain high levels of viability
throughout the entire experiment, this was not feasible. Any
reduction in parasite viability in the no-drug control wells will in-
crease variability and non-speciﬁc error, decreasing the consis-
tency and accuracy of the data. The IC50 usually is the most
robust and accurate measure of the overall susceptibility of a pop-
ulation because data is collected at concentrations both above and
below this value. This was also true of our data, thus the IC50 was
selected as the parameter of choice. Furthermore, with regard to
the planned use of this assay, if an LOE case is not due to compli-
ance failure, then all parasites in that dog would have established
in the presence of regular ML prophylaxis. Consequently, all worms
infecting the dog would be resistant, leading to reduced heteroge-
neity in the dose–response of the F2 generation. Thus, the IC50 is
the most logical and appropriate parameter for evaluating the sus-
ceptibility of any suspected-resistant D. immitis isolate with an
in vitro assay. In contrast, there is usually high variability at the
upper plateau of the dose–response, especially when 100% inhibi-
tion is not achievable. This tends to make the IC95 a highly unstable
parameter that is prone to variability-induced errors of
interpretation.
Macrocyclic lactone resistance in H. contortus and Cooperia
oncophora is well-established, and the LMIA has proven effective
in discriminating resistant from susceptible isolates (Kotze et al.,
2006; Demeler et al., 2010). Measuring these differences is also
dependent upon how well dose–response data ﬁt the statistical
model being used, and in this study we found noticeably higher
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eprinomectin than with ivermectin. This disparity is not unusual,
as in vitro responses in the LMIA have been reported to vary with
the ML compound used (Kotze et al., 2006). This group also found
that eprinomectin yielded superior results as compared to iver-
mectin in the LMIA. Gill and Lacey (1998) ﬁrst reported that the
optimal ML compound for use in an in vitro assay varies among as-
say type and parasite species, and thus needs to be determined
empirically by experimentation for each assay-species combina-
tion. This ﬁnding demonstrates that the drug used in a particular
in vitro bioassay has broad relevance and applicability for the en-
tire anthelmintic class it represents. For example, in the LDA, the
analog that provides the greatest discrimination between ML-sus-
ceptible and ML-resistant isolates of H. contortus and Trichostrongy-
lus spp. is avermectin aglycone (Gill and Lacey, 1998; Kaplan et al.,
2007), a drug that has poor efﬁcacy in vivo and has not been devel-
oped as an anthelmintic product. Consequently, it is unimportant
that eprinomectin is not used clinically for the prevention of heart-
worm infection. Future work will involve performing the LMIA
with suspected-resistant D. immitis isolates, and the testing of
additional ML compounds to determine whether eprinomectin or
another analog is the best choice for discriminating heartworm
populations of differing drug susceptibilities.
The suitability of the LMIA for assessing ML susceptibility in
ﬁlarioids must also be considered further. The LMIA is a motility-
based assay and the ML anthelmintics are known to cause paralysis
in gastrointestinal nematodes of ruminants (Boisvenue et al., 1983;
Folz et al., 1987). This rationale was the basis of the assay’s devel-
opment and validation as a diagnostic test for ML-resistance in
ruminant nematodes. Given the extremely high ML sensitivity of
D. immitis L3 and L4 stages, for which motility and migration are
critical in both the initial infection of the canine host and subse-
quent tissue migration, we assumed that the LMIA would be the
ideal assay for detecting ML resistance in this parasite. However,
we observed that the ML concentrations required to induce an
in vitro paralytic response were quite high. The preventive dose
of ivermectin (6 lg/kg), which yields 100% clinical efﬁcacy, pro-
duces peak plasma levels in the dog of approximately 3 ng/ml
(Daurio et al., 1992). In contrast, the present study demonstrated
an IC50 value of 4.56 lM (3.99 lg/ml) for ivermectin, and even at
20 lM concentrations (17.5 lg/ml ivermectin; 18.3 lg/ml eprino-
mectin) we failed to effect total migration inhibition. In vitro con-
centrations more than 6000 times higher than those achieved
in vivo could not come close to reaching the level of 100% inhibi-
tion. The disparity in drug level and the limited achievable efﬁcacy
challenge our assumption that the in vitro and in vivo responses of
D. immitis to MLs are comparable and lead us to believe that the
drug may be acting through at least two different mechanisms. In-
deed, the host immune response may be integral to ML activity in
D. immitis as indicated by research in other ﬁlarioids. In vitro treat-
ment of Brugia malayi microﬁlariae with ivermectin was reported
to interfere with protein secretion, which may unmask this para-
site to the host immune system and allow its clearance (Moreno
et al., 2010). Furthermore, studies with Acanthocheilonema viteae
microﬁlariae reported that, while this ﬁlarioid is unaffected by
nanomolar concentrations of ivermectin in vitro, it is subject to
cell-mediated cytotoxicity when treated in the presence of host
serum (Rao et al., 1987). Similar observations were reported for
Litomosoides carinii, though for this parasite, treatment with iver-
mectin before exposure to immune cells appeared to elicit a cyto-
toxic response when worms were later cultured in the absence of
drug (Zahner and Schmidtchen, 1994). These observations, both re-
cent and old, suggest that the ML mechanism of action in ﬁlarioid
parasites (clade III) may differ from that in the phylogenetically
distinct gastrointestinal nematodes (clade V). If this is true, thenit follows that in vitro bioassays developed for detecting ML resis-
tance in gastrointestinal nematodes will not be effective in ﬁlari-
oids like D. immitis. Further research will investigate these issues,
aiming to improve our understanding of the in vivo action of the
MLs. We hope that further elucidation of the mechanism by which
ML drugs kill these parasites will give us new insight into the effec-
tive measurement of ML susceptibility and, by extension, the diag-
nosis of resistance.Acknowledgements
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